- argenx SE at Barclays Global Healthcare Conference TranscriptMar 12, 2024
- Q4 2023 argenx SE Earnings Call TranscriptFeb 29, 2024€347.05 (-6.93%)Earnings
- argenx SE at JPMorgan Healthcare Conference TranscriptJan 08, 2024
- argenx SE Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus TranscriptDec 20, 2023
- argenx SE Investor Call TranscriptNov 28, 2023
- Q3 2023 argenx SE Earnings Call TranscriptOct 31, 2023€439.05 (+1.16%)Earnings
- argenx SE at Morgan Stanley Global Healthcare Conference TranscriptSep 11, 2023
- argenx SE at Citi BioPharma Conference TranscriptSep 06, 2023
- Q2 2023 argenx SE Earnings Call TranscriptJul 27, 2023€464.4 (-0.59%)Earnings
- argenx SE To Discuss the Adhere Results TranscriptJul 17, 2023
- argenx SE To Discuss Drug Administration Approval of VYVGART TranscriptJun 21, 2023
- argenx SE at Bank of America Global Healthcare Conference TranscriptMay 09, 2023
- Q1 2023 argenx SE Earnings Call TranscriptMay 04, 2023€350.4 (-2.23%)Earnings
- argenx SE at TD Cowen Health Care Conference TranscriptMar 06, 2023
- Q4 2022 argenx SE Earnings Call TranscriptMar 02, 2023€328 (-6.17%)Earnings
- argenx SE Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-09-2023 09:00 AM TranscriptJan 09, 2023
- argenx SE at Piper Sandler Healthcare Conference TranscriptNov 30, 2022
- argenx SE at Evercore ISI HealthCONx Conference (Virtual) TranscriptNov 29, 2022
- Q3 2022 argenx SE Earnings Call TranscriptOct 27, 2022€358 (-8.28%)Earnings
- Q2 2022 argenx SE Earnings Call TranscriptJul 28, 2022€363.85 (+0.93%)Earnings
- argenx SE at Goldman Sachs Global Healthcare Conference TranscriptJun 15, 2022
- argenx SE at Bank of America Healthcare Conference TranscriptMay 11, 2022
- Q1 2022 argenx SE Earnings Call TranscriptMay 05, 2022€303.75 (+11.67%)Earnings
- argenx SE Topline Phase 3 Data From ADAPT-SC Study Call TranscriptMar 22, 2022
- argenx SE at Cowen Health Care Conference (Virtual) TranscriptMar 07, 2022
- Q4 2021 argenx SE Earnings Call TranscriptMar 03, 2022€247.05 (-5.27%)Earnings
- argenx SE at JPMorgan Healthcare Conference (Virtual) TranscriptJan 10, 2022
- argenx SE To Discuss FDA Approval Call TranscriptDec 17, 2021
- Q3 2021 argenx SE Earnings Call TranscriptOct 28, 2021€238.8Earnings
- argenx SE at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 10, 2021
- Q2 2021 argenx SE Earnings Call TranscriptJul 29, 2021€253.85 (-0.88%)Earnings
- argenx SE virtual R&D Day Call TranscriptJul 20, 2021
- argenx SE at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 08, 2021
- Q1 2021 argenx SE Earnings Call TranscriptMay 14, 2021€217.05 (-0.02%)Earnings
- argenx SE Presents At Bank of America Global Research Healthcare Conference (Virtual) TranscriptMay 13, 2021
- Full Year 2020 argenx SE Earnings Call TranscriptMar 04, 2021€254.5 (-4.36%)Earnings
- argenx SE - Special Call TranscriptFeb 01, 2021
- argenx SE at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2021
- argenx SE at Stifel Virtual Healthcare Conference TranscriptNov 17, 2020
- Q3 2020 argenx SE Earnings Call TranscriptOct 22, 2020€212.8 (-3.49%)Earnings
- argenx SE at Bank of America Merrill Lynch Global Healthcare Conference (Virtual) TranscriptSep 17, 2020
- argenx SE at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 14, 2020
- Half Year 2020 argenx SE Earnings Call TranscriptJul 30, 2020€200.25 (-6.82%)Earnings
- argenx SE at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2020
- argenx SE Announces Positive Topline Results from Phase 3 ADAPT Trial of Efgartigimod in Patients with Generalized Myasthenia Gravis - Call TranscriptMay 26, 2020
- Q1 2020 argenx SE Earnings and Business Update Call TranscriptMay 14, 2020
- argenx SE at Bank of America Merrill Lynch Healthcare Conference (Virtual) TranscriptMay 12, 2020
- Q4 2019 argenx SE Earnings Call TranscriptFeb 27, 2020€133.5 (-6.25%)Earnings
- argenx SE at JPMorgan Healthcare Conference TranscriptJan 14, 2020
- argenx SE at Morgan Stanley Healthcare Conference TranscriptSep 09, 2019
- Q2 2019 argenx SE Earnings Call TranscriptAug 01, 2019€133.6 (+5.56%)Earnings
- argenx SE - Special Call TranscriptMay 22, 2019
- Q4 2018 argenx SE Earnings Call TranscriptFeb 28, 2019€116.8 (+1.92%)Earnings
argenx SE at Piper Sandler Healthcare Conference Transcript
Okay. I think we can go ahead and get started. My name is Ally Bratzel. I'm a biotech analyst here at Piper Sandler. It's my pleasure to introduce our next company, argenx. Joining us today, we have Karl Gubitz, Chief Financial Officer; and Keith Woods, Chief Operating Officer.
So thanks for joining us. This is going to be a fireside chat format. But before we jump into Q&A, just to level set for investors, Karl, could you just give a quick overview of argenx? The story and the setup into 2023?
Thank you very much, Ally. Good afternoon, everybody. Yes, 2022 has been a very busy and successful year for us. We've proved that we can add value across the value chain, not only both first-in-class, best-in-class drugs, design innovative trials, [getting] through the discovery and development programs and then launch.
We've launched in the U.S., Japan and in Europe and Germany in 2022. For a company of our size to launch in 3
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)